Every June, the United States observes Men’s Health Month, an awareness campaign first formalized in 1994 when Congress passed legislation establishing National Men’s Health Week….
United Therapeutics’ (NASDAQ: UTHR) FDA‑approved lung perfusion platform is an organ‑supply expansion story that supports the company’s broader lung‑transplant and xenotransplantation strategy, rather than a…
Biogen (NASDAQ: BIIB) is using AAIC 2026 to showcase the depth of its Alzheimer’s portfolio, including new Phase 2 data for its tau‑targeting antisense drug…
Aethlon Medical, Inc. (NASDAQ: AEMD) has announced new peer‑reviewed research supporting a mechanistic link between a novel long COVID biomarker and its Hemopurifier device, suggesting…
eXoZymes Inc (NASDAQ: EXOZ) picked up another non‑dilutive win and the stock responded, nudging higher after the company secured a new $2 million NIH grant…
Passage Bio (NASDAQ: PASG) is handing the keys to Remix Therapeutics in an all‑stock reverse merger that will take Remix public, rebrand the combined company…
June 24, 2026
Pulsenmore Rockets Higher as Ouma Health Deal Brings Home Ultrasound to Virtual Maternity Care
Pulsenmore (NASDAQ: PLSM) just went vertical after finally landing the kind of U.S. commercial partner its story has been missing. The stock jumped more than…
June 23, 2026
Lilly and Astellas Pick Over Sangamo’s Gene Therapy Assets as Biotech Slides Into Bankruptcy
Eli Lilly and Company (NYSE: LLY) and Astellas Pharma Inc. (OTCPK: ALPMY) are moving in to carve up key Sangamo Therapeutics, Inc. (OTCQB: SGMO) assets…
June 22, 2026
HIVE Digital’s Paraguay BUZZ AI Cloud Earns Columbia Stamp of Approval, Heads to NeurIPS
HIVE Digital Technologies Ltd. (NASDAQ: HIVE) is gaining credible third‑party validation for its Paraguay AI build‑out as a Columbia University team reports strong performance from…
June 22, 2026
BridgeBio’s Oral Infigratinib Shows Strong Phase 3 Growth Data in Children With Achondroplasia
BridgeBio Pharma Inc. (NASDAQ: BBIO) announced Phase 3 data for its oral achondroplasia therapy infigratinib from the PROPEL 3 trial at ICCBH 2026, putting a…
Biogen Inc. (Nasdaq: BIIB) is sharpening its immunology focus with an agreement to acquire privately held RayThera Inc., in a deal worth up to $1…
uniQure N.V. (NASDAQ: QURE) is rallying after the U.S. Food and Drug Administration agreed to an accelerated‑approval pathway for its Huntington’s disease gene therapy, AMT‑130,…